Zydus Lifesciences rose 2.80% to Rs 948 after the company announced the launch launch of Mirabegron Extended-Release Tablets in the US market, following the receipt of final approval from the United States Food and Drug Administration for the same.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.